DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Effect of the Honan intraocular pressure reducer to prevent vitreous reflux after intravitreal bevacizumab injection.

Author(s): Hong SW, Jee D.

Affiliation(s): Department of Ophthalmology and Visual Science, Bucheon St. Mary's Hospital, Seoul, Korea.

Publication date & source: 2012, Eur J Ophthalmol. , 22(4):615-9

PURPOSE: To evaluate the effect of the Honan intraocular pressure reducer (HIPR) on vitreous reflux during intravitreal (IVT) injection. METHODS: Prospective, comparative, controlled, investigator-blinded, randomized clinical study. Sixty eyes of 60 patients who underwent IVT injection were allocated into 2 groups with or without using the HIPR. Vitreous reflux was estimated by measuring largest diameter of the conjunctival bleb formed after IVT injection. Preoperative intraocular pressure (IOP) before and after application of the HIPR and IOP immediately postoperatively and 3 and 10 minutes postoperatively were evaluated. RESULTS: The mean amount of vitreous reflux was significantly less with the HIPR than without the HIPR (1.46±1.04 mm vs 2.61±1.37 mm; p<0.001). The preoperative IOP was significantly lower with the HIPR than without the HIPR (11.62±4.04 mmHg vs 16.26±3.86 mmHg; p=0.026). The 3-minute postoperative IOP was 31.34±3.16 mmHg with the HIPR and 32.61±5.62 mmHg without the HIPR (no statistical significance; p=0.345). CONCLUSIONS: The HIPR prevents vitreous reflux after IVT through a reduction in the preoperative IOP. However, the HIPR appears not to affect the postoperative course of transient IOP elevation.

Page last updated: 2013-02-10

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017